All In Biotech

Drug Trial Radar · NCT00474708

Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients

The Efficacy of Venlafaxine XR (Efexor XR®) Versus SSRIs & Conventional Antidepressants in Depressed Patients Switched From Prior Antidepressants in Psychiatric Outpatient Care Settings in China

Last checked: Nov 20, 2026Latest source record: Mar 5, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,151 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,151

Actual

Start

Apr 2007

Primary completion

Mar 2008

Study completion Mar 2008

Sponsor

Sponsor type
Industry
First posted
May 17, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, randomized, multi-center study conducted in a typical psychiatric outpatient practice in China. This study is intended to collect data on the efficacy and safety of venlafaxine XR (Efexor XR®) versus SSRIs and conventional antidepressants in depressed patients that previously failed antidepressant treatment. This data will be used to guide psychiatrists on recommendations for clinic use.

Conditions

  • Major Depressive Disorder

Interventions

  • EffexorDrug

  • SSRIDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients Achieving RemissionTime frame: 12 weeks

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Beijing, Beijing Municipality, China

  • Site not named

    Beijing, Beijing Municipality, China

  • Site not named

    Beijing, Beijing Municipality, China

  • Site not named

    Guangzhou, Guangdong, China

  • Site not named

    Guangzhou, Guangdong, China

  • Site not named

    Guangzhou, Guangdong, China

  • Site not named

    Guangzhou, Guangdong, China

  • Site not named

    Zhengzhou, Henan, China

  • Site not named

    Wuhan, Hubei, China

  • Site not named

    Changsha, Hunan, China

  • Site not named

    Nanjing, Jiangsu, China

  • Site not named

    Shenyang, Liaoning, China

  • Site not named

    Jinan, Shandong, China

  • Site not named

    Shanghai, Shanghai Municipality, China

  • Site not named

    Shanghai, Shanghai Municipality, China

  • Site not named

    Shanghai, Shanghai Municipality, China

  • Site not named

    Shanghai, Shanghai Municipality, China

  • Site not named

    Shanghai, Shanghai Municipality, China

  • Site not named

    Shanghai, Shanghai Municipality, China

  • Site not named

    Shanghai, Shanghai Municipality, China

  • Site not named

    Xian, Shanxi, China

  • Site not named

    Tianjin, Tianjin Municipality, China

  • Site not named

    Hangzhou, Zhejiang, China

  • Site not named

    Hangzhou, Zhejiang, China

  • Site not named

    Huzhou, Zhejiang, China

  • Site not named

    Suzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.